Vivo Capital, Versant Ventures and other U.S. institutional investors invest in Biotie Technologies Corp.

Avance advises Vivo Capital, Versant Ventures and other U.S. institutional investors in their EUR 27.5 million investment in convertible notes issued by Biotie Therapies Corp. In addition to convertibles notes, the investors subscribed for warrants exercisable for shares in Biotie.